Skip links

Rescue Therapy

Cell-based Therapies for Mitochondrial Dysfunction

Rescue Therapy

Cell-based Therapies for Mitochondrial Dysfunction

Targeting mitochondrial dysfunction

IMEL develops cell-based therapies to restore mitochondrial function for the treatment of genetic diseases and age-related indications. Our unique approach enables replacing the dysfunctional mitochondria with healthy mitochondria in a cell to reprogram its functionality.

Mitochondrial dysfunction is the core of a vast range of diseases

Mitochondria are the primary source of energy production in the cell. Found in nearly every cell in the body, they are critical for healthy organ function. Mitochondrial dysfunction has clinical manifestation mainly in multiple systems involving organs that have high energy demands, e.g., brain, skeletal muscles, heart, and pancreas.

Mitochondrial dysfunction is one of the hallmarks of aging

Acquired mitochondrial dysfunction is involved in many age-related disorders such as neurodegenerative diseases, cancer, and inflammatory diseases.

  • Alzheimer’s disease
  • Immunosenescence
  • Pulmonary fibrosis
  • Chronic kidney disease
  • COPD
  • Metabolic disease
  • Cardiovascular disease
  • Liver disease

Inherited mitochondrial disfunction are manifested in multiple genetic diseases

Inherited mitochondrial disorders are caused by mutations in mitochondrial or nuclear DNA and is involved in more than 50 genetic-related diseases, including:

  • Leigh syndrome
  • LHON
  • cPEO
  • KSS
  • Bath Syndrome
  • Friedreich’s Ataxia

The new era
of mitochondrial therapies

Our approach:
Rescuing mitochondrial function

At IMEL, our cell-based therapy rescues mitochondrial function by replacing dysfunctional mitochondria and increasing the number of healthy mitochondria in a cell (the MirC process). Doing so we restore energy production and function to cells, organs, and systems. The technology can potentially be applied to a wide range of inherited and age-associated indications that lack treatment options today.

IMEL’s products: Autologous mitochondrial replaced cells

We are developing autologous mitochondria-replaced cells (MirC) as an intravenously infused cell therapy for the treatment of patients with mitochondrial dysfunctions. The patients' cells are collected, undergo the MirC process, and returned to the patient.

1: Collect

Collect blood cells via apheresis

2: Select

Select target cells

3: Replace

Replace target cells with the healthy donor mitochondria

4: Prepare

Prepare cell-based product for treatment

5: Infuse

Mitochondria replaced product

Lead Team

Board of Directors

Advisory board

Our investors

Looking to collaborate?